In search for selective ligands for the muscarinic acetylcholine receptor (MR) subtype M 2 , the dimeric ligand approach, that is combining two pharmacophores in one and the same molecule, was pursued. Different types (agonists, antagonists, orthosteric, and allosteric) of monomeric MR ligands were combined by various linkers with a dibenzodiazepinone-type MR antagonist, affording five types of heterodimeric compounds ("DIBA-xanomeline," "DIBA-TBPB," "DIBA-77-LH-28-1," "DIBA-propantheline," and "DIBA-4-DAMP"), which showed high M 2 R affinities (pK i > 8.3). The heterodimeric ligand UR-SK75 (46) exhibited the highest M 2 R affinity and selectivity [pK i (M 1 R−M 5 R): 8.84, 10.14, 7.88, 8.59, and 7.47]. Two tritium-labeled dimeric derivatives ("DIBA-xanomeline"-type: [ 3 H]UR-SK71 ([ 3 H]44) and "DIBA-TBPB"-type: [ 3 H]UR-SK59 ([ 3 H]64)) were prepared to investigate their binding modes at hM 2 R. Saturation-binding experiments showed that these compounds address the orthosteric binding site of the M 2 R. The investigation of the effect of various allosteric MR modulators [gallamine (13), W84 (14), and LY2119620 (15)] on the equilibrium (13−15) or saturation (14) binding of [ 3 H]64 suggested a competitive mechanism between [ 3 H]64 and the investigated allosteric ligands, and consequently a dualsteric binding mode of 64 at the M 2 R.
INTRODUCTION
Muscarinic acetylcholine receptors (MRs) belong to the class A G-protein coupled receptor (GPCR) superfamily and comprise five receptor subtypes in humans (designated M 1 R−M 5 R). 1−4 Whereas the M 1 R, M 3 R, and M 5 R receptors were reported to couple with G q proteins, the M 2 R and M 4 R receptors bind to G i/o proteins. 5 MRs represent interesting drug targets, for instance, for the treatment of Alzheimer's disease and schizophrenia. 6, 7 Because of the high conservation of the orthosteric (acetylcholine) binding site, 8−10 there is lack of highly subtype selective (orthosteric) ligands, hampering therapeutic approaches such as the treatment of cognitive decline by centrally acting selective M 1 R agonists or M 2 R antagonists. 11 However, in addition to the orthosteric binding pocket, MRs were reported to exhibit distinct allosteric binding sites, which are less conserved and can potentially be exploited to develop subtype selective ligands. 12−17 The M 2 R was the first GPCR described to be subjected to allosteric modulation, 18−20 and several dualsteric M 2 R ligands (e.g., 7 21 and 10, 22, 23 Figure  1A ) and allosteric M 2 R modulators (e.g., 13, 20 14, 18 and 15, 24, 25 Figure 1B) were identified. Dimerization of GPCR ligands can result in an increased receptor affinity and improved selectivity. 26, 27 Bivalent (dimeric) ligands were described for various GPCRs, such as opioid, 28 histamine, 29, 30 dopamine, 31−33 adenosine, 33−35 and neuropeptide Y 36−38 receptors, not least to investigate receptor dimerization. Likewise, the design of dualsteric (bitopic) ligands, that is, hybrid derivatives that simultaneously address the orthosteric and allosteric sites of one and the same receptor protomer, represents an approach toward improved subtype selectivity. 19,39−42 For example, rationally designed hybrid MR ligands derived from the orthosteric agonist oxotremorine (2) and hexamethonium-like allosteric modulators (e.g., compound 16, Figure 1C ) showed increased subtype selectivity compared to 2. 43 Similarily, the MR ligand THRX-160209 (compound 17, Figure 1C ) was reported to exhibit a higher M 2 R affinity and selectivity than the corresponding monovalent ligands and was suggested to bind to the M 2 receptor in a multivalent manner. 44 Pyridobenzodiazepinone derivative 7 and the structurally closely related dibenzodiazepinone derivative 8 ( Figure 1A ) represent tricyclic M 2 R-preferring MR antagonists. 45, 46 Trankle et al. suggested a dualsteric binding mode of 7 at the M 2 receptor, 21 and a hybrid ligand formed of 7 and allosteric modulator 14 was reported to show a pronounced positive cooperativity with 5, pointing at a new way for the development of allosteric enhancers. 47, 48 This study was aimed at the design, synthesis, and pharmacological evaluation of heterodimeric MR ligands derived from 8, comprising five combinations of 8 with reported orthosteric or allosteric MR ligands: "8−xanomeline (1)," "8−TBPB (11) ," "8−77-LH-28-1 (12) ," "8−4-DAMP (3)," and "8−propantheline (4) ." Xanomeline (1) (cf. Figure  1A) is a M 1 and M 4 receptor preferring MR agonist. 49 Compound 11 (cf. Figure 1B ) was reported to selectively activate M 1 receptors through an allosteric mechanism, as shown by mutagenesis and molecular pharmacology studies; 50−52 in other reports, 11 was described as a bitopic M 1 R ligand. 53 Likewise, compound 12 (cf. Figure 1B) was suggested to be a bitopic M 1 R ligand. 54 MR antagonists 3 and 4 (cf. Figure 1A ) are nonselective orthosteric MR antagonists with high affinities [K i (3, 45, 55 In addition to the heterodimeric ligands, one monomeric and four homodimeric ligands derived from xanomeline, one monomeric and two homodimeric ligands derived from 8, and a monomeric ligand derived from 11 were prepared as reference compounds. Furthermore, two radiolabeled heterodimeric ligands (types "8−11" and "8−1") were prepared and characterized by saturation binding [including experiments in the presence of allosteric modulators (Schild-like analysis)], kinetic investigations, and competition-binding studies.
RESULTS AND DISCUSSION
2.1. Chemistry. Monomeric reference compound 22 and homodimeric xanomeline-derived ligand 25 were prepared by N-alkylation of homopiperazine derivative 21 using bromide 20 [followed by removal of the tert-butoxycarbonyl (Boc) group] and by alkylation of piperazine (24) using bromide 23, respectively (Scheme 1). Treatment of amine 26 with octanedioyl dichloride or decanedioyl dichloride in the presence of triethylamine yielded homodimeric xanomelinetype compounds 27 and 28, respectively. Likewise, amidation of terephthalic acid with amine 26, using 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC)/1-hydroxybenzotriazole hydrate (HOBt) as coupling reagent, afforded homodimeric ligand 29 containing a rigid central linker moiety. N-alkylation of 21 using bromide 30, followed by removal of the Boc group, afforded TBPB derivative 31 (Scheme 1).
The "8−11" type heterodimeric ligand 34 was prepared by N-alkylation of compound 32 using bromide 33; N-alkylation , the latter suggested to exhibit a dualsteric binding mode at the M 2 R. 23 
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Article of 21 using 33, followed by removal of the Boc group yielded monomeric reference compound 35 (Scheme 2). Likewise, Nalkylation of piperazine derivatives 36 and 37, using bromide 33, gave the "8−4" type heterodimeric ligands 38 and 39. The "8−1" type heterodimeric ligand 43 was prepared through Nalkylation of compound 40 by applying a mixture of bromides 20 and 33, followed by Boc-deprotection (Scheme 2). Homodimeric ligand 41, 23 obtained as a "byproduct" (after Boc-deprotection), was isolated as well. Compound 41 was recently used as an amine precursor for the preparation of a tritium-labeled homodimeric MR ligand. 23 Amine 43 was propionylated to give congener 44. The "8−1" type ligand 46 was obtained by N-alkylation of 45 by bromide 33 (Scheme 2). The "8−3" type heterodimeric ligand 48 and the "8−12" type ligand 50 were synthesized by alkylation of compound 47 using bromide 33 and by alkylation of amine 9 22 (cf. Figure 1A ) using bromide 49, respectively (Scheme 2). Treatment of 40 with a mixture of bromides 30 and 33, followed by Bocdeprotection, gave the "8−11" type heterodimeric ligand 51, which contains a rigid homopiperazine moiety in between the pharmacophores. As in the case of the synthesis of 43, homodimeric "byproduct" 41 was isolated. Propionylation of 51 gave congener 52 (Scheme 2). Homodimeric ligand 54 was obtained by treating an excess of compound 47 with bromide 53 (Scheme 2). Regarding the syntheses of 43 and 51, it should be mentioned that the respective non-DIBA type homodimeric ligands, resulting from a double alkylation of 40 with bromides 20 or 30, were formed as well, but were not isolated because of interference with other impurities [preparative high-performance liquid chromatography (HPLC)].
Amidation of isophthalic acid derivative 57 by applying a mixture of amines 55 and 56, followed by Boc-deprotection, afforded heterodimeric ligand 60 and homodimeric ligand 58 (Scheme 3). Propionylation of 58 and 60 gave congeners 59 and 61, respectively. By analogy, heterodimeric ligands 63, 66, 69, and 72 were obtained by amidation of 57 using the amine mixtures 55/62, 55/65, 55/68, and 55/71, respectively, and subsequent Boc-deprotection (Scheme 3). Propionylation of 63, 66, and 69 at the central linker moiety afforded propionamide congeners 64, 67, and 70. It should be noted that the respective non-DIBA type homodimeric ligands, generated by double amidation of 57 with amines 56, 62, 65, 68, or 71, were formed but were not isolated (cf. Scheme 3). Table  1 .
All compounds containing a dibenzodiazepinone moiety showed high M 2 R affinity (pK i > 8.3). Whereas homodimeric derivatives (25, 27−29) of MR agonist 1 exhibited an increased M 2 R affinity (pK i > 7.7) compared to the parent compound (pK i of 1: 6.55, see Table 3 ); the opposite was found in the case of MR antagonist 3 [pK i = 7.09 ± 0.04, mean ± standard error of the mean (SEM) from two independent experiments] and a homodimeric derivative of 3 (compound 54, pK i = 6.05, Table  1 ). The "8−1" type heterodimeric ligand 46 displayed the highest M 2 R affinity (pK i = 10.14, Table 1 ). Steep curve slopes (≤−1.79) were observed for 43, 51, 60, 61, 64, 67, and 70, indicating a complex mechanism of binding (e.g., the involvement of more than one binding site).
2.2.2. MR Receptor Subtype Selectivity. Selected dibenzodiazepinone-type heterodimeric ligands (34, 38, 39, 44, 46, 48, 50, 52, 61, 64, 67, 70 , and 72) and monomeric dibenzodiazepinone derivative 35, containing an aminofunctionalized homopiperazine moiety, were also investigated by equilibrium competition binding at the MR subtypes M 1 , M 3 , M 4 , and M 5 with [ 3 H]5 as the radioligand (Table 1) . For all compounds, there was a preference for the M 2 R. Except for 38, the M 1 R and M 4 R affinities were higher than the M 3 R and M 5 R affinities, that is, the selectivity profile was M 2 > M 1 ≈ M 4 > M 3 /M 5 (34, 39, 44, 46, 48, 50, 52, 61, 64, 67, 70 , and 72) and M 2 > M 1 ≈ M 5 > M 3 > M 4 in the case of 38 (Table 1) . Compound 46, showing the highest M 2 R affinity among the studied MR ligands, exhibited a more pronounced M 2 R selectivity than the pyridobenzodiazepinone-type ligand 7 (cf. Figure 1A ), 45 the MR antagonist tripitramine 56 containing three pyridobenzodiazepinone moieties, as well as the recently reported dibenzodiazepinone derivatives 10 and 19 (cf. Figure  1C ). 23 Displacement of [ 3 H]5 by 46 as well as by heterodimeric ligands 44 and 64, which were prepared as tritiated ligands (see below), from M x Rs (determined at CHO-hM x R cells, x = 1−5) is illustrated in Figure 2 . ACS Omega Article 2.3. Effect on IP1 Accumulation. As previously reported for homodimeric dibenzodiazepinone derivative 19, 23 the homodimeric xanomeline-type ligand 25 and the heterodimeric dibenzodiazepinone-type ligands 44, 46, and 64 were investigated with respect to M 2 R agonism and antagonism in an IP accumulation assay ( Figure 3 ). Like 19, compounds 44, 46, and 64 did not induce an IP1 accumulation when investigated in the agonist mode ( Figure 3A ), but completely suppressed the effect of CCh when studied in the antagonist mode ( Figure 3B ), revealing that the combination of the agonist xanomeline (1) with a dibenzodiazepinone-type antagonist in one molecule (e.g., 44) resulted in a loss of agonistic activity. Interestingly, homodimeric ligand 25, which is derived from MR agonist 1, proved to be a M 2 R antagonist in contrast to parent compound 1 (Figure 3 ). The pK b values of 44, 46, and 64 (cf. Figure 3B) were lower compared to the respective pK i values (cf. Figure 4A ). Additionally, the tritiated derivative of heterodimeric ligand 64 was prepared from 63 and [ 3 H]42 ( Figure 4A ). The chemical stabilities of the "cold" analogues 44 and 64 were investigated under assaylike conditions [phosphate-buffered saline (PBS) pH 7.4] for over 48 h. 44 and 64 proved to be stable under these conditions (cf. SI Figure 1 Figure 4C ,E). Figure 5 ). As previously reported for [ 3 H]19, 23 the extent of unspecific binding strongly depended on the assay conditions: in the case of experiments performed at intact adherent cells (white/transparent 96-well plates), unspecific binding was considerably higher compared to experiments performed at cell homogenates, which preclude the unspecific binding of the radioligand to the microplate ( Figure 5 ). 23 The apparent K d values amounted to 1.0 and 0.081 nM (cell homogenates, Table 2 ). As orthosteric antagonist 6 (used to determine unspecific binding) completely Figure 6A ,C, Table 2 ). Whereas the "8−1" type heterodimeric ligand [ 3 H]44 dissociated completely from the M 2 R (t 1/2 = 47 min, cf. Figure  6B , Table 2 ), the dissociation of the "8−11" type dimeric ligand [ 3 H]64 was incomplete, reaching a plateau at approximately 47% of initially M 2 R-bound [ 3 H]64 (t 1/2 = 35 min, cf. Figure  6D , Table 2 ). An incomplete ligand dissociation, which might be attributed to conformational adjustments of the receptor upon ligand binding 57 or an enhanced rebinding capability of the dimeric ligand, 58 
Characterization of [ 3 H]44 and [ 3 H]64. Saturationbinding experiments with [ 3 H]44 and [ 3 H]64 at intact CHO-hM 2 R cells or CHO-hM 2 R cell homogenates yielded monophasic saturation isotherms (
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Article 10, or 14. Likewise, orthosteric ligands 1 and 6, dualsteric ligands 7 and 10, as well as allosteric modulators 13−15 (cf. Figure 1 ) completely displaced [ 3 H]64 from the M 2 R-specific binding sites. (SI Figure 2B , Supporting Information). For most of the investigated MR ligands, the respective pK i values were in good agreement with the binding data obtained from competition binding with [ 3 H]5 (Table 3 ). However, the pK i values of compounds 1, 6, 7, and 10, determined in the presence of [ 3 H]64, were consistently lower (up to 1 log unit in the case of 7) than pK i values from the competition-binding experiments with [ 3 H]5. This is in agreement with the (in part) irreversible M 2 R binding of [ 3 H]64 (cf. Figure 6D) , which compromises its use as a molecular tool for the determination of binding constants of nonlabeled ligands, as was also reported for homodimeric MR ligand [ Figure  7) , as recently reported for homodimeric radioligand [ 3 H]19. 23 As in the case of [ 3 H]19, 23 this Schild-like analysis resulted in rightward-shifted saturation isotherms of [ 3 H]64 ( Figure 7A ) and a linear Schild plot with a slope not different from unity ( Figure 7B ), which is consistent with a competitive mechanism between [ 3 H]64 and allosteric M 2 R ligand 14. With regard to the fact that [ 3 H]64 binds to the orthosteric binding site of the M 2 R (see above), these results strongly support a dualsteric binding mode of 64 at the human M 2 R. The "pA 2 " value of 7.16, obtained for 14 from the Schild regression ( Figure 7B) , was in accordance with the reported M 2 R binding data of 14 (pK X 7.50 59 ).
CONCLUSIONS
Linking orthosteric (1, 3, and 4) and allosteric (11 and 12) MR ligands with a M 2 R preferring dibenzodiazepinone-type MR antagonist (8) Table 1 ), as also reported for monomeric dibenzodiazepinone-type ligands, 22 suggested a minor influence of the second pharmacophore on M 2 R binding, indicating that the high M 2 R affinity of these compounds is mediated by the "dibenzodiazepinone" pharmacophore, which binds most likely to the orthosteric binding site of the M 2 R. This is supported by the proposed binding mode of 10 and 19 at the M 2 R, 23 
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Article as a second pharmacophore (43, 44, 46, 60, and 61) proved to be M 2 R-preferring ligands. Moreover, the prototypical heterodimeric ligands 44 and 46 were shown to be M 2 R antagonists (cf. Figure 3 ). Concerning the "8−1" type heterodimeric ligands, one can speculate about the contribution of the pharmacophore of 1 to M 2 R binding because the homodimeric derivatives of 1 (compounds 25, 27−29) exhibited considerably higher M 2 R affinities compared to 1. This work confirms that dibenzodiazepinone-type MR ligands represent a promising class of compounds for the development of highly selective M 2 R ligands with a high receptor affinity based on the dualsteric ligand approach. 23 and 123 62 were prepared according to described procedures. 
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Millipore water was used throughout for the preparation of buffers and HPLC eluents. If moisture-free conditions were required, reactions were performed in dried glassware under an inert atmosphere (argon). Anhydrous THF was obtained by distillation over sodium, and anhydrous CH 2 Cl 2 was prepared by distillation over P 2 O 5 after predrying over CaCl 2 . Reactions were monitored by thin-layer chromatography using aluminum plates coated with silica gel (Merck silica gel 60 F 254 , thickness 0.2 mm). Spots were detected by ultraviolet (UV) light (254 or 366 nm) or by staining using 0.3% solution of ninhydrin in nbutanol (amines) or iodine. Column chromatography was performed in glass columns on silica gel (Merck silica gel 60, 63−200 μm). Flash chromatography was performed on an Intelli Flash-310 Flash-Chromatography Workstation (Varian, Darmstadt, Germany). Polypropylene reaction vessels (1.5 or 2 mL) with a screw cap (Sud-Laborbedarf, Gauting, Germany) were used for the synthesis of radioligands ([ 3 H]44 and [ 3 H] 64) for small-scale reactions, for the investigation of chemical stabilities (44 and 64) , and for the preparation and storage of stock solutions. Melting points were measured with a Buchi 530 (Buchi, Essen, Germany) apparatus and are uncorrected. Microwave-assisted reactions were performed with an Initiator 2.0 synthesizer (Biotage, Uppsala, Sweden). NMR spectra were recorded on a Bruker AVANCE 300 (7.05 T), Bruker AVANCE III HD 400 (9.40 T), or a Bruker AVANCE III HD 600 spectrometer equipped with a cryogenic probe (14.1 T) (Bruker, Karlsruhe, Germany). Abbreviations for the multiplicities of the signals are s (singlet), d (doublet), t (triplet), dd (doublet-of-doublet), q (quartet), m (multiplet), and brs (broad-singlet). Infrared (IR) spectra were measured with a Nicolet 380 FT-IR spectrophotometer (Thermo Electron Corporation). Low-resolution mass spectrometry was performed on a Finnigan SSQ 710A instrument [chemical ionization mass spectrometry (CI-MS, Thermo Finnigan, San Jose, CA). High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an electrospray ionization source. Preparative HPLC was performed on a system from Knauer (Berlin, Germany) consisting of two K-1800 pumps and a K-2001 detector. Except for compound 54, a Kinetex-XB C18 column, 5 μm, 250 × 21 mm (Phenomenex, Aschaffenburg, Germany) served as the stationary phase at a flow rate of 15 mL/min. For the purification of 54, a Nucleodur 100-5 C18 column, 5 μm, (34, 35, 38, 39, 43, 44, 46, 48, 50, 52, 58−61, 63, 64, 66, 69 , and 72): due to a slow rotation about the exocyclic amide group on the NMR time scale, two isomers (ratios provided in the experimental protocols) were evident in the 1 H-and 13 C-NMR spectra.
4.2. Compound Characterization. Nondescribed intermediate compounds were characterized by 1 H-and 13 C-NMR spectroscopy, HRMS, and melting point (if applicable). Target compounds were characterized by 1 H-and 13 C-NMR spectroscopy, HRMS, and RP-HPLC analysis. In addition, compounds 44 and 64 were analyzed by IR spectroscopy. Purities determined by analytical RP-HPLC amounted to >95%. , and the preparation of CHO-hM 2 R cell homogenates are described elsewhere. 23 4.5. IP1 Accumulation Assay. The IP1 accumulation assay was performed as described elsewhere. 23 4.6. Radioligand Binding. Equilibrium competition-binding experiments with [ 3 H]5 were performed at intact CHO-hM x R cells (x = 1−5) as described previously, 22 but the total volume per well was 200 μL, that is, in the case of total binding, the wells were filled with 180 μL of L15 medium followed by addition of L15 medium (20 μL) containing [ 3 H]5 (10-fold concentrated). To determine the unspecific binding and the effect of a compound of interest on the equilibrium binding [ 3 H]5, the wells were filled with 160 μL of L15 medium followed by addition of L15 medium (20 μL) containing 6 or the compound of interest (10-fold concentrated) and L15 medium (20 μL 23 The radioligand concentration was 2 and 0.6 nM, respectively. The incubation was started in reversed order after different periods of time (120−1 min). After last addition of the radioligand, homogenates were collected on filter mats using the Harvester. Unspecific binding was determined in the presence of 6 (500fold excess to the radioligand). For M 2 R dissociation experiments with [ 3 H]44 and [ 3 H]64, performed at CHO-hM 2 R cell homogenates, the procedure was essentially the same as for saturation-binding experiments with [ 3 H]19 at CHO-hM 2 R cell homogenates. 23 The preincubation (60 min) of the cell homogenates with the radioligand ([ 3 H]44: 4 nM, [ 3 H]64: 0.6 nM) was started in reversed order after different periods of time ([ 3 H]44: between 180 and 1 min and [ 3 H]64: between 150 and 1 min) by addition of L15 medium (10 μL) containing the radioligand (10-fold concentrated) to the wells preloaded with L15 medium (80 μL) and cell homogenates (10 μL). The dissociation was started by addition of 10 μL of L15 medium containing 6 (40 and 6 μM, respectively) and was stopped by collection and washing of the homogenates using the harvester. To determine unspecific binding, 6 (1000-fold excess to the radioligand) was added during the preincubation step. 4.7. Data Processing. Retention (capacity) factors were calculated from retention times (t R ) according to k = (t R − t 0 )/ t 0 (t 0 = dead time). Data from the IP1 accumulation assay and radioligand-binding assays [saturation binding (including Schild-like analysis), association and dissociation kinetics, and equilibrium competition binding] were processed as described previously. 23 Statistical significance (curve slopes) was assessed by a t-test (one-sample, two-tailed). Propagated errors were calculated according to the Gaussian law of errors. 
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